1. Jennette J. Overview of the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Clinical and experimental nephrology. 2013;17(5):603-606. doi: 10.1007/s10157-013-0869-6
2. Новиков П.И., Семенкова Е.Н., Моисеев С.В. Современная номенклатура системных васкулитов. Клиническая фармакология и терапия. 2013;22(1):70-74. [Novikov P, Semenkova E, Moiseev S. Modern nomenclature od systemic vasculitides. Clinical pharmacology and therapy. 2013;22(1):70-74. (In Russ.)]
3. Мухин Н.А., Розина Т.П, Новиков П.И. и др. Узелковый полиартериит, ассоциированный с вирусом гепатита В (клинический разбор). Клиническая медицина. 2015;93(6):5-13. [Mukhin N, Rozina T, Novikov P, et al. Nodular polyarteritis associated with hepatitis B virus (a case study). Klinicheskaia meditsina. 2016;93(6):5-13. (In Russ.)]
4. Игнатова Т.М., Чернова О.А., Бурневич Э.З., Милованова С.Ю. Успешное лечение HCV-криоглобулинемического васкулита тяжелого течения с помощью CD-20 моноклональных антител и противовирусных препаратов. Клиническая медицина. 2014;92(8):62-64. [Ignatova T, Chernova O, Burnevich E, Milovanova S. Successful treatment of severe HCV-cryoglobulinemic vasculitis with the use of CD20 monoclonal antibodies and antiviral agents. Klinicheskaia meditsina. 2014;92(8):62-64. (In Russ.)]
5. Mukhtyar C, Guillevin L, Cid M, et al. EULAR recommendations for the management of large vessel vasculitis. Annals of the rheumatic diseases. 2009; 68(3):318-23. doi: 10.1136/ard.2008.088351
6. Мухин Н.А., Мешков А.Д., Новиков П.И. и др. Гигантоклеточный артериит: клинические проявления и методы ранней диагностики. Клиническая фармакология и терапия. 2015;24(3):79-85. [Mukhin N, Meshkov A, Novikov P, et al. Giant cell arteritis: clinical picture, outcomes and early diagnosis. Clinical pharmacology and therapy. 2015;24(3):79-85. (In Russ.)]
7. Мухин Н.А., Смитиенко И.О., Новиков П.И., Семенкова Е.Н., Моисеев С.В. Артериит Такаясу: трудности диганостики, лечение и исходы в когортном исследовании у 128 больных. Клиническая фармакология и терапия. 2014; 23 (3): 55-61. [Mukhin N, Smitienko I, Novikov P, Semenkova E, Moiseev S. Clinical manifestations and outcomes of Takayasu arteritis in the cohort study in 128 patients. Clinical pharmacology and therapy. 2014;23(3): 55-61. (In Russ.)]
8. Kotter I, Henes J, Wagner A, Loock J, Gross W. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature. Clinical and experimental rheumatology. 2012; 30(1)(suppl 70):114-29.
9. Bienvenu B, Ly K, Lambert M, et al. Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). La Revue de Médecine Interne. 2016;37(3):154-65. doi: 10.1016/j.revmed.2015.12.015
10. Seror R, Baron G, Hachulla E, et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Annals of the rheumatic diseases. 2014;73(12):2074-2081. doi: 10.1136/annrheumdis-2013-203586
11. Hoffman G, Cid M, Rendt-Zagar K, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Annals of internal medicine. 2007;146(9):621-630.
12. Martínez-Taboada V, Rodríguez-Valverde V, Carreño L, et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Annals of the rheumatic diseases. 2008;67(5):625-630.
13. Loricera J, Blanco R, Hernández J, et al. Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients. Seminars in arthritis and rheumatism. 2015; 44(6):717-723. doi: 10.1016/j.semarthrit. 2014.12.005
14. Régent A, Redeker S, Deroux A, et al. Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients. The Journal of rheumatology. 2016;43(8):1547-1552. doi: 10.3899/jrheum.151252
15. Villiger P, Adler S, Kuchen S, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. The Lancet. 387(10031):1921-1927. doi: 10.1016/S0140-6736(16)00560-2
16. Сатыбалдыев А.М., Сатыбалдыева М.А., Насонов Е.Л. Тоцилизумаб в лечении ревматической полимиалгии и гигантоклеточного артериита. Клиническая фармакология и терапия. 2017;26(1):47-53. [Satybaldyev A, Satybaldyevа M, Nasonov E. Tocilizumab for polymyalgia rheumatic and giant cell arteritis. Clinical pharmacology and therapy. 2017;26(1):47-53. (In Russ.)]
17. Stone J, Tuckwell K, Dimonaco S, et al. Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. Paper presented at: ACR/ARHP 2016 Annual Meeting. November 13, 2016. Available at: http://acrabstracts.org/abstract/efficacy-and-safety-of-tocilizumab-in-patients-with-giant-cell-arte.... Accessed March 27, 2017.
18. Conway R, O'Neill L, O'Flynn E, et al. Ustekinumab for the treatment of refractory giant cell arteritis. Annals of the rheumatic diseases. 2016; 75(8):1578-1579. doi: 10.1136/annrheumdis-2016-209351
19. Langford C, Cuthbertson D, Ytterberg S, et al. A randomized, double-blind trial of abatacept (CTLA4-IG) for the treatment of giant cell arteritis. Arthritis & Rheumatology. [Epub ahead of print] doi: 10.1002/art.40044
20. Novikov P, Meshkov A, Moiseev S. Positron emission tomography in giant cell arteritis: a new diagnostic tool? Annals of the Rheumatic Disease. 2014;73(11):e70. doi: 10.1136/annrheumdis-2014-206227
21. Hoffman G, Merkel P, Brasington R, Lenschow D, Liang P. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis and rheumatism. 2004;50(7): 2296-2304. doi:10.1002/art.20300
22. Comarmond C, Plaisier E, Dahan K, et al. Anti TNF-alpha in refractory Takayasu's arteritis: cases series and review of the literature. Autoimmunity reviews/ 2012; 11(9):678-684. doi: 10.1016/j.autrev. 2011. 11.025
23. Новиков П.И., Смитиенко И.О., Моисеев С.В. Эффективность продолжительного лечения ингибиторами фактора некроза опухоли-α при артериите Такаясу, рефрактерном к стандартной иммуносупрессивной терапии. Клиническая фармакология и терапия. 2013;22(2):44-48. [Novikov P, Smitienko I, Moiseev S. Tumor necrosis factor-alpha inhibitors in patients with Takayasu arteritis refractory to standard immunosuppressive treatment. Clinical pharmacology and therapy. 2013; 22(2):44-48. (In Russ.)]
24. Novikov P, Smitienko I, Moiseev S. Tumor necrosis factor alpha inhibitors in patients with Takayasu's arteritis refractory to standard immunosuppressive treatment: cases series and review of the literature. Clinical rheumatology. 2013;32(12):1827-1832. doi: 10.1007/s10067-013-2380-6
25. Loricera J, Blanco R, Hernandez J, et al. Tocilizumab in patients with Takayasu arteritis: a retrospective study and literature review. Clinical and Experimental Rheumatology. 2016; 34(3) (suppl 97):44-53.
26. Park M, Lee S, Park Y, Lee S. Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. Rheumatology (Oxford, England). 2006; 45(5):545-548. doi: 10.1093/rheumatology/ kei266
27. Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis and rheumatism. 2008;58(4):1197-1200. doi: 10.1002/art.23373
28. Mekinian A, Comarmond C, Resche-Rigon M, et al. Efficacy of Biological-Targeted Treatments in Takayasu Arteritis: Multicenter, Retrospective Study of 49 Patients. Circulation. 2015;132(18):1693-1700. doi: 10.1161/circulationaha.114.014321
29. Langford C, Cuthbertson D, Ytterberg S, et al. A randomized, double-blind trial of abatacept (CTLA4-ig) for the treatment of Takayasu's arteritis. Arthritis & Rheumatology. 2017 [epub ahead of print]. doi: 10.1002/art.4003
30. O’Connor T, Carpenter H, Bidari S, Waters M, Hedna V. Role of inflammatory markers in Takayasu arteritis disease monitoring. BMC Neurology. 2014; 14:62. doi: 10.1186/1471-2377-14-62
31. Smitienko I, Atyasova E, Moiseev S, Novikov P. MR Angiography for Evaluation of Vascular Inflammation in Patients with Takayasu's Arteritis. Paper presented at: The 18th Inernational Vasculitis and ANCA Workshop. March 25-28, 2017. Available at: http://www.anca2017. tokyo/abstracts.html. Accessed March 27, 2017.
32. Nakagomi D, Jayne D. Outcome assessment in Takayasu arteritis. Rheumatology (Oxford). 2016; 55(7):1159-71. doi: 10.1093/rheumatology/kev366
33. Goglin S, Chung S. Current Treatment of Cryoglobulinemic Vasculitis. Current Treatment Options in Rheumatology. 2016;2(2):213-224. doi: 10.1007/s40674-016-0048-5
34. Ferri C, Greco F, Longombardo G, et al. Association between hepatitis C virus and mixed cryoglobulinemia [see comment]. Clinical and experimental rheumatology. 1991; 9(6):621-624.
35. Милованова C.Ю., Козловская Л.В., Гордовская Н.Б. Полиморфизм клинических проявлений риоглобулинемического васкулита, ассоциированного с хроническим гепатитом С. Альманах клинической медицины. 2014; 30:46-51. [Milovanova S, Kozlovskaya L, Gordovskaya N. Polymorphism of clinical manifestations of cryoglobulinemia-related vasculitis associated with chronic hepatitis C virus infection. Almanac of Clinical Medicine. 2014; 30:46-51. (In Russ.)] doi: 10.18786/2072-0505-2014-30-46-51 
36. Ignatova T, Chernova O, Novikov P, Moiseev S. HCV-associated cryoglobulinaemic vasculitis: triple/dual antiviral treatment and/or rituximab? Annals of the rheumatic diseases. 2014; 73(9):e58. doi: 10.1136/annrheumdis-2014-205997. 
37. Saadoun D, Thibault V, Si Ahmed S, et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Annals of the rheumatic diseases. 2016;75(10):1777-1782. doi: 10.1136/annrheumdis-2015-208339
38. Ferri C, Giuggioli D, Cazzato M, Sebastiani M, Mascia M, Zignego A. HCV-related cryoglobulinemic vasculitis: an update on its etiopathogenesis and therapeutic strategies. Clinical and experimental rheumatology. 2003; 21(6)(suppl 32):78-84.
39. De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis and rheumatism. 2012; 64(3):843-853. doi: 10.1002/art. 34331
40. Saadoun D, Resche Rigon M, Pol S, et al. PegIFNalpha/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis. Journal of hepatology. 2015; 62(1):24-30. doi: 10.1016/j.jhep.2014.08.015
41. Saadoun D, Thibault V, Si Ahmed S, et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Annals of the rheumatic diseases. 2016; 75(10): 1777-82. doi: 10.1136/annrheumdis-2015-208339
42. Bonacci M, Lens S, Londoño M, et al. Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus Associated Cryoglobulinemia Treated With Direct-Acting Antivirals. Clinical Gastroenterology and Hepatology. 2017;15(4):575-583. doi: 10.1016/j.cgh.2016.09.158
43. Landau D, Saadoun D, Halfon P, et al. Relapse of hepatitis C virus–associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis & Rheumatism. 2008; 58(2):604-611. doi: 10.1002/art.23305
44. Artemova M, Abdurakhmanov D, Ignatova T, Mukhin N. Persistent HCV-associated Cryoglobulinemic Vasculitis Following Virus Eradication after Direct-Acting Antivirals Therapy. Hepatology. 2016; [epub ahead of print]. doi: 10.1002/hep.28981
45. Moiseev S, Novikov P, Mukhin N. HCV-associated cryoglobulinemia vasculitis: are its days numbered? Annals of the rheumatic diseases.2017;76(3):5. doi: 10.1136/annrheumdis-2016-210636
46. Novikov P, Smitienko I, Bulanov N, Zykova A, Moiseev S. Testing for antineutrophil cytoplasmic antibodies (ANCAs) in patients with systemic vasculitides and other diseases. Annals of the rheumatic diseases. 2016; (epub ahead of print). doi: 10.1136/annrheumdis-2016-210890
47. Damoiseaux J, Csernok E, Rasmussen N, et al. Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen-specific immunoassays. Annals of the rheumatic diseases. 2016; 76(4):647-653. doi: 10.1136/annrheumdis-2016-209507
48. Mukhtyar C, Flossmann O, Hellmich B, et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Annals of the rheumatic diseases. 2008;67(7):1004-1010. doi: 10.1136/ard.2007.071936
49. Flossmann O, Berden A, de Groot K, et al. Long-term patient survival in ANCA-associated vasculitis. Annals of the rheumatic diseases. 2011; 70(3):488-494. doi: 10.1136/ard.2010.137778
50. Novikov P, Moiseev S, Kuznetsova E, Semenkova E, Mukhin N. Changing patterns of clinical severity and risk of mortality in granulomatosis with polyangiitis over four decades: the Russian experience. Rheumatology International. 2015; 35(5):891-898. doi:10.1007/ s00296-014-3154-4
51. Hoffman G, Kerr G, Leavitt R, et al. Wegener granulomatosis: an analysis of 158 patients. Annals of internal medicine. 1992;116(6): 488-498. doi: 10.7326/0003-4819-116-6-488
52. Faurschou M, Sorensen I, Mellemkjaer L, et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. The Journal of rheumatology. 2008; 35(1):100-105.
53. de Groot K, Harper L, Jayne D, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Annals of internal medicine. 2009; 150(10):670-680. doi: 10.7326/0003-4819-150-10-200905190-00004
54. Harper L, Morgan M, Walsh M, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Annals of the rheumatic diseases. 2012; 71(6):955-960. doi: 10.1136/annrheumdis-2011-200477
55. Jayne D, Rasmussen N, Andrassy K, et al. A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies. New England Journal of Medicine. 2003; 349(1):36-44. doi: 10.1056/NEJMoa020286
56. Stone J, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. The New England journal of medicine. 2010; 363(3):221-232. doi: 10.1056/NEJMoa0909905
57. Jones R, Tervaert J, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. The New England journal of medicine. 2010; 363(3):211–220. doi: 10.1056/NEJMoa 0909169
58. Yates M, Watts R, Bajema I, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Annals of the rheumatic diseases. 2016;75(9):1583-1594. doi: 10.1136/annrheumdis-2016-209133
59. Новиков П.И., Зыкова А.С., Смитиенко И.О., Моисеев С.В. Лечение АНЦА-ассоциированных васкулитов: рекомендации EULAR\ERA-EDTA 2016 года. Клиническая фармакология и терапия. 2017;26(1):80-87. [ Novikov P, Zykova A, Smitienko I, Moiseev S. Treatmant for ANCA-associated vasculitides 2016 EULAR/ERA-EDTA guidelines. Clinical pharmacology and therapy. 2016;26(1):80-87. (In Russ.)]
60. Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis. The New England Journal of Medicine. 2014;371(19):1771-1780. doi: 10.1056/NEJMoa1404231 
61. Бекетова Т.В., Александрова Е.Н, Новоселова Т.М. и др. Российский опыт применения моноклональных антител к В-лимфоцитам (Ритуксимаб) при системных васкулитах, ассоциированных с антинейтрофильными цитоплазматическими антителами (предварительные результаты российского регистра НОРМА). Научно-практическая ревматология. 2014;52(2):147-158. [Beketova T, Aleksandrova E, Novoselova T, et al. Russian experience with using monoclonal antibodies to B-lymphocytes (rituximab) in systemic vasculitides associated with neutrophil cytoplasmic antibodies (preliminary results of the Russian Register NORMA). Rheumatology Science and Practice. 2014;52(2):147–158. (In Russ.)] doi:10.14412/1995-4484-2014-147-158 
62. Ананьева Л.П., Соловьев С.К., Бекетова Т.В. и др. Анти-В-клеточная терапия при иммуновоспалительных ревматических заболеваниях: эффективность и переносимость у 229 больных. Научно-практическая ревматология. 2014;52(5):495–506. [Ananieva L, Soloviyov S, Beketova T, et al. Anti-B-cell therapy at immune inflammatory rheumatic diseases: efficacy and tolerability in 229 patients. Rheumatology Science and Practice. 2014;52(5):495-506. (In Russ.)] doi:10.14412/1995-4484-2014-495-506
63. Novikov P, Moiseev S, Shevtsova T, Smitienko I. Short-term Efficacy and Safety of Biosimilar Rituximab in Patients with Systemic Vasculitides. Paper presented at: The 18th Inernational Vasculitis and ANCA Workshop. March 25-28, 2017. Available at: http://www.anca2017. tokyo/abstracts.html. Accessed March 27, 2017.
64. Walsh M, Merkel P, Peh C, et al. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials. 2013;14:3.  doi: 10.1186/1745-6215-14-73
65. Lenert A, Lenert P. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents. Drug design, development and therapy. 2015; 9: 333-347. doi: 10.2147/DDDT.S67264
66. Mackay F, Schneider P, Rennert P, Browning J. BAFF and APRIL: a tutorial on B cell survival. Annual review of immunology. 2003; 21:231-264. doi: 10.1146/annurev.immunol.21.120601.141152
67. Schiemann B, Gommerman J, Vora K, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science (New York, NY). 2001;293(5537):2111-2114. doi: 10.1126/science.1061964
68. Bamberg C, Mackay C, Lee H, et al. The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction. The Journal of biological chemistry. 2010; 285(10):7633-7644. doi: 10.1074/jbc. M109.092106
69. Jayne D, Bruchfeld A, Harper L, et al. MO039Successful steroid replacement in ANCA-associated vasculitis with C5A receptor inhibitor CCX168 in phase 2 randomised (CLEAR). Nephrology Dialysis Transplantation. 2016; 31(suppl 1):45. doi: 10.1093/ndt/gfw137.01
70. Merkel PA, Niles J, Jimenez R, et al. A Randomized Clinical Trial of CCX168, an Orally Administered C5aR Inhibitor for Treatment of Patients with ANCA-Associated Vasculitis [abstract]. Arthritis and Rheumatology. 2016; 68 (suppl 10). Paper presented at: 2016 ACR/ARHR Annual Meeting. November 13, 2016. Available at: http://acrabstracts.org/abstract/a-randomized-clinical-trial-of-ccx168-an-orally-administered-c5ar-i... March 27, 2017.
71. Novikov P, Moiseev S, Bulanov N, Shchegoleva E. Bortezomib in refractory ANCA-associated vasculitis: a new option? Annals of the rheumatic diseases. 2016;75(1):9. doi: 10.1136/annrheumdis-2015-207947
72. Тареев Е.М., Семенкова Е.Н. Астматический вариант узелкового периартериита. Клиническая медицина. 1969;7:28-34. [Tareev E, Semenkova E. Asthmatic form of nodular polyangiitis. Klinicheskaia meditcina. 1969;7: 28-34. (In Russ.)]
73. Семенкова Е.Н. Системные васкулиты. Москва: Медицина, 1988. [Semenkova E. Systemic vasculitides. Meditcina (Moscow), 1988. (In Russ)]
74. Загвоздкина Е.С., Новиков П.И., Моисеев С.В. Особенности клинических проявлений и течения эозинофильного гранулематоза с полиангиитом в зависимости от наличия антител к цитоплазме нейтрофилов. Клиническая фармакология и терапия. 2017;26(1):24-30. [Zagvozdkina E, Novikov P, Moiseev S. Clinical features of eosinophilic granulematosis with polyanggiits in ANCA-positive and ANCA-negative patients. Clinical pharmacology and therapy. 2017;26(1):24-30. (In Russ.)]
75. Sinico R, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis and Rheumatism. 2005;52(9):2926-2935. doi: 10.1002/art.21250
76. Cottin V, Bel E, Bottero P, et al. Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): A study of 157 patients by the Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires and the European Respiratory Society Taskforce on eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Autoimmunity Reviews. 2017;16(1):1-9. doi: 10.1016/j.autrev.2016.09.018
77. Groh M, Pagnoux C, Baldini C, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA). Consensus Task Force recommendations for evaluation and management. European journal of internal medicine. 2015; 26(7):545-553. doi: 10.1016/j.ejim. 2015.04. 022
78. Puéchal X, Pagnoux C, Baron G, et al. Prevent relapses in patients with systemic necrotizing vasulitides without poor-prognosis factors? A multicenter, double-blind randomized controlled trial. Annals of the rheumatic diseases. 2016; 75(suppl 2):77. doi: 10.1136/annrheumdis-2016-eular.6204
79. Moiseev S, Novikov P. Five Factor Score in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss; EGPA): to use or not to use? Annals of the rheumatic diseases. 2014;73(3)e.12. doi: 10.1136/annrheumdis-2013-204809
80. Mohammad A, Hot A, Arndt F, et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg–Strauss) Annals of the Rheumatic Diseases. 2016;75:396-401. doi: 10.1136/annrheumdis-2014-206095
81. Novikov P, Moiseev S, Smitienko I, Zagvozdkina E. Rituximab as induction therapy in relapsing eosinophilic granulomatosis with polyangiitis: A report of 6 cases. Joint, bone, spine. 2016;83(1):81-84. doi: 10.1016/j.jbspin.2015.04.016
82. Novikov P, Moiseev S. Biologic therapy for eosinophilic granulomatosis with polyangiitis: comment on the article by Jachiet et al. Arthritis & Rheumatology. 2016; [Epub ahead of print] doi: 10.1002/art.40015
83. Jachiet M, Samson M, Cottin V, et al. Anti-IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss): Data on Seventeen Patients. Arthritis & rheumatology (Hoboken, NJ). 2016; 68(9): 2274-2282. doi: 10.1002/art.39663

________________________________________________

1. Jennette J. Overview of the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Clinical and experimental nephrology. 2013;17(5):603-606. doi: 10.1007/s10157-013-0869-6
2. Novikov P, Semenkova E, Moiseev S. Modern nomenclature od systemic vasculitides. Clinical pharmacology and therapy. 2013;22(1):70-74. (In Russ.)
3. Mukhin N, Rozina T, Novikov P, et al. Nodular polyarteritis associated with hepatitis B virus (a case study). Klinicheskaia meditsina. 2016;93(6):5-13. (In Russ.)
4. Ignatova T, Chernova O, Burnevich E, Milovanova S. Successful treatment of severe HCV-cryoglobulinemic vasculitis with the use of CD20 monoclonal antibodies and antiviral agents. Klinicheskaia meditsina. 2014;92(8):62-64. (In Russ.)
5. Mukhtyar C, Guillevin L, Cid M, et al. EULAR recommendations for the management of large vessel vasculitis. Annals of the rheumatic diseases. 2009; 68(3):318-23. doi: 10.1136/ard.2008.088351
6. Mukhin N, Meshkov A, Novikov P, et al. Giant cell arteritis: clinical picture, outcomes and early diagnosis. Clinical pharmacology and therapy. 2015;24(3):79-85. (In Russ.)
7. Mukhin N, Smitienko I, Novikov P, Semenkova E, Moiseev S. Clinical manifestations and outcomes of Takayasu arteritis in the cohort study in 128 patients. Clinical pharmacology and therapy. 2014;23(3): 55-61. (In Russ.)
8. Kotter I, Henes J, Wagner A, Loock J, Gross W. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature. Clinical and experimental rheumatology. 2012; 30(1)(suppl 70):114-29.
9. Bienvenu B, Ly K, Lambert M, et al. Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). La Revue de Médecine Interne. 2016;37(3):154-65. doi: 10.1016/j.revmed.2015.12.015
10. Seror R, Baron G, Hachulla E, et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Annals of the rheumatic diseases. 2014;73(12):2074-2081. doi: 10.1136/annrheumdis-2013-203586
11. Hoffman G, Cid M, Rendt-Zagar K, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Annals of internal medicine. 2007;146(9):621-630.
12. Martínez-Taboada V, Rodríguez-Valverde V, Carreño L, et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Annals of the rheumatic diseases. 2008;67(5):625-630.
13. Loricera J, Blanco R, Hernández J, et al. Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients. Seminars in arthritis and rheumatism. 2015; 44(6):717-723. doi: 10.1016/j.semarthrit. 2014.12.005
14. Régent A, Redeker S, Deroux A, et al. Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients. The Journal of rheumatology. 2016;43(8):1547-1552. doi: 10.3899/jrheum.151252
15. Villiger P, Adler S, Kuchen S, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. The Lancet. 387(10031):1921-1927. doi: 10.1016/S0140-6736(16)00560-2
16. Satybaldyev A, Satybaldyevа M, Nasonov E. Tocilizumab for polymyalgia rheumatic and giant cell arteritis. Clinical pharmacology and therapy. 2017;26(1):47-53. (In Russ.)
17. Stone J, Tuckwell K, Dimonaco S, et al. Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. Paper presented at: ACR/ARHP 2016 Annual Meeting. November 13, 2016. Available at: http://acrabstracts.org/abstract/efficacy-and-safety-of-tocilizumab-in-patients-with-giant-cell-arte.... Accessed March 27, 2017.
18. Conway R, O'Neill L, O'Flynn E, et al. Ustekinumab for the treatment of refractory giant cell arteritis. Annals of the rheumatic diseases. 2016; 75(8):1578-1579. doi: 10.1136/annrheumdis-2016-209351
19. Langford C, Cuthbertson D, Ytterberg S, et al. A randomized, double-blind trial of abatacept (CTLA4-IG) for the treatment of giant cell arteritis. Arthritis & Rheumatology. [Epub ahead of print] doi: 10.1002/art.40044
20. Novikov P, Meshkov A, Moiseev S. Positron emission tomography in giant cell arteritis: a new diagnostic tool? Annals of the Rheumatic Disease. 2014;73(11):e70. doi: 10.1136/annrheumdis-2014-206227
21. Hoffman G, Merkel P, Brasington R, Lenschow D, Liang P. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis and rheumatism. 2004;50(7): 2296-2304. doi:10.1002/art.20300
22. Comarmond C, Plaisier E, Dahan K, et al. Anti TNF-alpha in refractory Takayasu's arteritis: cases series and review of the literature. Autoimmunity reviews/ 2012; 11(9):678-684. doi: 10.1016/j.autrev. 2011. 11.025
23. Novikov P, Smitienko I, Moiseev S. Tumor necrosis factor-alpha inhibitors in patients with Takayasu arteritis refractory to standard immunosuppressive treatment. Clinical pharmacology and therapy. 2013; 22(2):44-48. (In Russ.)
24. Novikov P, Smitienko I, Moiseev S. Tumor necrosis factor alpha inhibitors in patients with Takayasu's arteritis refractory to standard immunosuppressive treatment: cases series and review of the literature. Clinical rheumatology. 2013;32(12):1827-1832. doi: 10.1007/s10067-013-2380-6
25. Loricera J, Blanco R, Hernandez J, et al. Tocilizumab in patients with Takayasu arteritis: a retrospective study and literature review. Clinical and Experimental Rheumatology. 2016; 34(3) (suppl 97):44-53.
26. Park M, Lee S, Park Y, Lee S. Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. Rheumatology (Oxford, England). 2006; 45(5):545-548. doi: 10.1093/rheumatology/ kei266
27. Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis and rheumatism. 2008;58(4):1197-1200. doi: 10.1002/art.23373
28. Mekinian A, Comarmond C, Resche-Rigon M, et al. Efficacy of Biological-Targeted Treatments in Takayasu Arteritis: Multicenter, Retrospective Study of 49 Patients. Circulation. 2015;132(18):1693-1700. doi: 10.1161/circulationaha.114.014321
29. Langford C, Cuthbertson D, Ytterberg S, et al. A randomized, double-blind trial of abatacept (CTLA4-ig) for the treatment of Takayasu's arteritis. Arthritis & Rheumatology. 2017 [epub ahead of print]. doi: 10.1002/art.4003
30. O’Connor T, Carpenter H, Bidari S, Waters M, Hedna V. Role of inflammatory markers in Takayasu arteritis disease monitoring. BMC Neurology. 2014; 14:62. doi: 10.1186/1471-2377-14-62
31. Smitienko I, Atyasova E, Moiseev S, Novikov P. MR Angiography for Evaluation of Vascular Inflammation in Patients with Takayasu's Arteritis. Paper presented at: The 18th Inernational Vasculitis and ANCA Workshop. March 25-28, 2017. Available at: http://www.anca2017. tokyo/abstracts.html. Accessed March 27, 2017.
32. Nakagomi D, Jayne D. Outcome assessment in Takayasu arteritis. Rheumatology (Oxford). 2016; 55(7):1159-71. doi: 10.1093/rheumatology/kev366
33. Goglin S, Chung S. Current Treatment of Cryoglobulinemic Vasculitis. Current Treatment Options in Rheumatology. 2016;2(2):213-224. doi: 10.1007/s40674-016-0048-5
34. Ferri C, Greco F, Longombardo G, et al. Association between hepatitis C virus and mixed cryoglobulinemia [see comment]. Clinical and experimental rheumatology. 1991; 9(6):621-624.
35. Milovanova S, Kozlovskaya L, Gordovskaya N. Polymorphism of clinical manifestations of cryoglobulinemia-related vasculitis associated with chronic hepatitis C virus infection. Almanac of Clinical Medicine. 2014; 30:46-51. (In Russ.) doi: 10.18786/2072-0505-2014-30-46-51 
36. Ignatova T, Chernova O, Novikov P, Moiseev S. HCV-associated cryoglobulinaemic vasculitis: triple/dual antiviral treatment and/or rituximab? Annals of the rheumatic diseases. 2014; 73(9):e58. doi: 10.1136/annrheumdis-2014-205997. 
37. Saadoun D, Thibault V, Si Ahmed S, et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Annals of the rheumatic diseases. 2016;75(10):1777-1782. doi: 10.1136/annrheumdis-2015-208339
38. Ferri C, Giuggioli D, Cazzato M, Sebastiani M, Mascia M, Zignego A. HCV-related cryoglobulinemic vasculitis: an update on its etiopathogenesis and therapeutic strategies. Clinical and experimental rheumatology. 2003; 21(6)(suppl 32):78-84.
39. De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis and rheumatism. 2012; 64(3):843-853. doi: 10.1002/art. 34331
40. Saadoun D, Resche Rigon M, Pol S, et al. PegIFNalpha/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis. Journal of hepatology. 2015; 62(1):24-30. doi: 10.1016/j.jhep.2014.08.015
41. Saadoun D, Thibault V, Si Ahmed S, et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Annals of the rheumatic diseases. 2016; 75(10): 1777-82. doi: 10.1136/annrheumdis-2015-208339
42. Bonacci M, Lens S, Londoño M, et al. Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus Associated Cryoglobulinemia Treated With Direct-Acting Antivirals. Clinical Gastroenterology and Hepatology. 2017;15(4):575-583. doi: 10.1016/j.cgh.2016.09.158
43. Landau D, Saadoun D, Halfon P, et al. Relapse of hepatitis C virus–associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis & Rheumatism. 2008; 58(2):604-611. doi: 10.1002/art.23305
44. Artemova M, Abdurakhmanov D, Ignatova T, Mukhin N. Persistent HCV-associated Cryoglobulinemic Vasculitis Following Virus Eradication after Direct-Acting Antivirals Therapy. Hepatology. 2016; [epub ahead of print]. doi: 10.1002/hep.28981
45. Moiseev S, Novikov P, Mukhin N. HCV-associated cryoglobulinemia vasculitis: are its days numbered? Annals of the rheumatic diseases.2017;76(3):5. doi: 10.1136/annrheumdis-2016-210636
46. Novikov P, Smitienko I, Bulanov N, Zykova A, Moiseev S. Testing for antineutrophil cytoplasmic antibodies (ANCAs) in patients with systemic vasculitides and other diseases. Annals of the rheumatic diseases. 2016; (epub ahead of print). doi: 10.1136/annrheumdis-2016-210890
47. Damoiseaux J, Csernok E, Rasmussen N, et al. Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen-specific immunoassays. Annals of the rheumatic diseases. 2016; 76(4):647-653. doi: 10.1136/annrheumdis-2016-209507
48. Mukhtyar C, Flossmann O, Hellmich B, et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Annals of the rheumatic diseases. 2008;67(7):1004-1010. doi: 10.1136/ard.2007.071936
49. Flossmann O, Berden A, de Groot K, et al. Long-term patient survival in ANCA-associated vasculitis. Annals of the rheumatic diseases. 2011; 70(3):488-494. doi: 10.1136/ard.2010.137778
50. Novikov P, Moiseev S, Kuznetsova E, Semenkova E, Mukhin N. Changing patterns of clinical severity and risk of mortality in granulomatosis with polyangiitis over four decades: the Russian experience. Rheumatology International. 2015; 35(5):891-898. doi:10.1007/ s00296-014-3154-4
51. Hoffman G, Kerr G, Leavitt R, et al. Wegener granulomatosis: an analysis of 158 patients. Annals of internal medicine. 1992;116(6): 488-498. doi: 10.7326/0003-4819-116-6-488
52. Faurschou M, Sorensen I, Mellemkjaer L, et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. The Journal of rheumatology. 2008; 35(1):100-105.
53. de Groot K, Harper L, Jayne D, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Annals of internal medicine. 2009; 150(10):670-680. doi: 10.7326/0003-4819-150-10-200905190-00004
54. Harper L, Morgan M, Walsh M, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Annals of the rheumatic diseases. 2012; 71(6):955-960. doi: 10.1136/annrheumdis-2011-200477
55. Jayne D, Rasmussen N, Andrassy K, et al. A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies. New England Journal of Medicine. 2003; 349(1):36-44. doi: 10.1056/NEJMoa020286
56. Stone J, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. The New England journal of medicine. 2010; 363(3):221-232. doi: 10.1056/NEJMoa0909905
57. Jones R, Tervaert J, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. The New England journal of medicine. 2010; 363(3):211–220. doi: 10.1056/NEJMoa 0909169
58. Yates M, Watts R, Bajema I, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Annals of the rheumatic diseases. 2016;75(9):1583-1594. doi: 10.1136/annrheumdis-2016-209133
59. Novikov P, Zykova A, Smitienko I, Moiseev S. Treatmant for ANCA-associated vasculitides 2016 EULAR/ERA-EDTA guidelines. Clinical pharmacology and therapy. 2016;26(1):80-87. (In Russ.)
60. Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis. The New England Journal of Medicine. 2014;371(19):1771-1780. doi: 10.1056/NEJMoa1404231 
61. Beketova T, Aleksandrova E, Novoselova T, et al. Russian experience with using monoclonal antibodies to B-lymphocytes (rituximab) in systemic vasculitides associated with neutrophil cytoplasmic antibodies (preliminary results of the Russian Register NORMA). Rheumatology Science and Practice. 2014;52(2):147–158. (In Russ.) doi:10.14412/1995-4484-2014-147-158 
62. Ananieva L, Soloviyov S, Beketova T, et al. Anti-B-cell therapy at immune inflammatory rheumatic diseases: efficacy and tolerability in 229 patients. Rheumatology Science and Practice. 2014;52(5):495-506. (In Russ.) doi:10.14412/1995-4484-2014-495-506
63. Novikov P, Moiseev S, Shevtsova T, Smitienko I. Short-term Efficacy and Safety of Biosimilar Rituximab in Patients with Systemic Vasculitides. Paper presented at: The 18th Inernational Vasculitis and ANCA Workshop. March 25-28, 2017. Available at: http://www.anca2017. tokyo/abstracts.html. Accessed March 27, 2017.
64. Walsh M, Merkel P, Peh C, et al. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials. 2013;14:3.  doi: 10.1186/1745-6215-14-73
65. Lenert A, Lenert P. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents. Drug design, development and therapy. 2015; 9: 333-347. doi: 10.2147/DDDT.S67264
66. Mackay F, Schneider P, Rennert P, Browning J. BAFF and APRIL: a tutorial on B cell survival. Annual review of immunology. 2003; 21:231-264. doi: 10.1146/annurev.immunol.21.120601.141152
67. Schiemann B, Gommerman J, Vora K, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science (New York, NY). 2001;293(5537):2111-2114. doi: 10.1126/science.1061964
68. Bamberg C, Mackay C, Lee H, et al. The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction. The Journal of biological chemistry. 2010; 285(10):7633-7644. doi: 10.1074/jbc. M109.092106
69. Jayne D, Bruchfeld A, Harper L, et al. MO039Successful steroid replacement in ANCA-associated vasculitis with C5A receptor inhibitor CCX168 in phase 2 randomised (CLEAR). Nephrology Dialysis Transplantation. 2016; 31(suppl 1):45. doi: 10.1093/ndt/gfw137.01
70. Merkel PA, Niles J, Jimenez R, et al. A Randomized Clinical Trial of CCX168, an Orally Administered C5aR Inhibitor for Treatment of Patients with ANCA-Associated Vasculitis [abstract]. Arthritis and Rheumatology. 2016; 68 (suppl 10). Paper presented at: 2016 ACR/ARHR Annual Meeting. November 13, 2016. Available at: http://acrabstracts.org/abstract/a-randomized-clinical-trial-of-ccx168-an-orally-administered-c5ar-i... March 27, 2017.
71. Novikov P, Moiseev S, Bulanov N, Shchegoleva E. Bortezomib in refractory ANCA-associated vasculitis: a new option? Annals of the rheumatic diseases. 2016;75(1):9. doi: 10.1136/annrheumdis-2015-207947
72. Тареев Е.М., Семенкова Е.Н. Астматический вариант узелкового периартериита. Клиническая медицина. 1969;7:28-34. [Tareev E, Semenkova E. Asthmatic form of nodular polyangiitis. Klinicheskaia meditcina. 1969;7: 28-34. (In Russ.)]
73. Семенкова Е.Н. Системные васкулиты. Москва: Медицина, 1988. [Semenkova E. Systemic vasculitides. Meditcina (Moscow), 1988. (In Russ)]
74. Zagvozdkina E, Novikov P, Moiseev S. Clinical features of eosinophilic granulematosis with polyanggiits in ANCA-positive and ANCA-negative patients. Clinical pharmacology and therapy. 2017;26(1):24-30. (In Russ.)
75. Sinico R, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis and Rheumatism. 2005;52(9):2926-2935. doi: 10.1002/art.21250
76. Cottin V, Bel E, Bottero P, et al. Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): A study of 157 patients by the Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires and the European Respiratory Society Taskforce on eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Autoimmunity Reviews. 2017;16(1):1-9. doi: 10.1016/j.autrev.2016.09.018
77. Groh M, Pagnoux C, Baldini C, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA). Consensus Task Force recommendations for evaluation and management. European journal of internal medicine. 2015; 26(7):545-553. doi: 10.1016/j.ejim. 2015.04. 022
78. Puéchal X, Pagnoux C, Baron G, et al. Prevent relapses in patients with systemic necrotizing vasulitides without poor-prognosis factors? A multicenter, double-blind randomized controlled trial. Annals of the rheumatic diseases. 2016; 75(suppl 2):77. doi: 10.1136/annrheumdis-2016-eular.6204
79. Moiseev S, Novikov P. Five Factor Score in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss; EGPA): to use or not to use? Annals of the rheumatic diseases. 2014;73(3)e.12. doi: 10.1136/annrheumdis-2013-204809
80. Mohammad A, Hot A, Arndt F, et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg–Strauss) Annals of the Rheumatic Diseases. 2016;75:396-401. doi: 10.1136/annrheumdis-2014-206095
81. Novikov P, Moiseev S, Smitienko I, Zagvozdkina E. Rituximab as induction therapy in relapsing eosinophilic granulomatosis with polyangiitis: A report of 6 cases. Joint, bone, spine. 2016;83(1):81-84. doi: 10.1016/j.jbspin.2015.04.016
82. Novikov P, Moiseev S. Biologic therapy for eosinophilic granulomatosis with polyangiitis: comment on the article by Jachiet et al. Arthritis & Rheumatology. 2016; [Epub ahead of print] doi: 10.1002/art.40015
83. Jachiet M, Samson M, Cottin V, et al. Anti-IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss): Data on Seventeen Patients. Arthritis & rheumatology (Hoboken, NJ). 2016; 68(9): 2274-2282. doi: 10.1002/art.39663

П.И. НОВИКОВ1, А.С. ЗЫКОВА2, С.В. МОИСЕЕВ1,2

1 ФГБОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава РФ, Москва, Россия;
2 МГУ им. М.В. Ломоносова, Москва, Россия

________________________________________________

P.I. NOVIKOV1, A.S. ZYKOVA2, S.V. MOISEEV1, 2 

1 Sechenov First Moscow State Medical University, Moscow, Russia;
2 Lomonosov Moscow State University, Moscow, Russia